Zentel

Quick links to important sections

Zentel

Selected form

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Zentel

What is Zentel?

Zentel is an anthelmintic medication designed to treat a variety of parasitic worm infections. It belongs to a class of drugs known as benzimidazoles, which work by interfering with the biological processes of parasites, ultimately leading to their elimination from the body.

Active Ingredient and Mechanism

The active substance in Zentel is albendazole. This compound functions by preventing the parasite from absorbing glucose, which is its primary source of energy. By inhibiting the polymerization of tubulin—a protein essential for the structural integrity and metabolic function of the parasite's cells—albendazole causes the energy depletion and death of the larvae and adult worms.

Primary Applications

Zentel is used to address several types of intestinal and systemic parasitic conditions, including:

  • Intestinal Nematodes: Common infections such as roundworm, whipworm, pinworm, and hookworm.
  • Cestodes: Certain types of tapeworm infections, including beef tapeworm and pork tapeworm.
  • Systemic Infections: More complex conditions where parasites affect tissues outside the digestive tract, such as hydatid disease or neurocysticercosis.

Therapeutic Goal

The medication is formulated to target parasites at multiple stages of their life cycle, including the egg, larval, and adult stages. By clearing these organisms, Zentel helps resolve the symptoms associated with the infection and prevents further complications related to parasitic infestation.

What side effects are possible with Zentel?

Possible Side Effects and Safety Information

The safety profile for Zentel (Albendazole) is documented by regulatory authorities, with potential adverse reactions classified by frequency and affected physiological system. The most Common effects listed in official labeling include headache, abdominal pain, nausea, vomiting, and transient elevations of hepatic enzymes. Reversible hair thinning, or alopecia, is also documented as a common reaction.


System-Organ Classifications and Serious Risks

Adverse reactions are grouped into System-Organ Classes (SOC) such as Hepatobiliary disorders (liver) and Blood and the lymphatic system disorders (bone marrow). Regulatory documentation identifies a risk of serious adverse reactions, including severe bone marrow suppression (e.g., pancytopenia or aplastic anemia) and rare reports of acute liver failure. Very rare but serious cutaneous reactions like Stevens-Johnson syndrome are also noted in postmarketing reports.


Safety Restrictions and Monitoring

The official label mandates safety monitoring for all patients. Routine checks of complete blood cell counts and liver enzymes (transaminases) are required due to the documented risks of hematological and hepatic toxicity. Treatment must be suspended if clinically significant changes in these laboratory values occur. Albendazole is contraindicated in pregnancy due to the potential for fetal harm; females of childbearing age are required to use effective contraception during and for a specified period following therapy. In patients treated for neurocysticercosis, neurological symptoms such as seizures or increased intracranial pressure may be observed soon after treatment initiation, related to the inflammatory response to parasite death.

Overdose and Emergency Response

Overdose and When to Seek Help

This section details the officially documented manifestations and required emergency procedures for an overdose of Zentel (Albendazole), as outlined in government regulatory information.

Overdose Scope Description (Based on Regulatory Labeling)
Documented Manifestations No untoward effects were reported in a documented human case involving the ingestion of at least 16 grams over a 12-hour period.
Exposure-Related Notes Manifestations such as alopecia, pancytopenia, and elevated hepatic enzymes are documented in case reports involving prolonged, high-dose use that significantly exceeded therapeutic levels, though they are not specified as acute overdose signs.
No Specific Antidote Regulatory documents confirm that no specific antidote is known for Albendazole overdose.

Required Emergency Action

Official regulatory guidance mandates that immediate steps be taken in all cases of suspected overdose:

  • Seek immediate medical attention for evaluation and monitoring.
  • Contact the Poison Control Center immediately for advice, as directed by national health authorities.

Management of an overdose event is centered on symptomatic treatment and general supportive measures to maintain clinical stability. Procedural interventions, including the use of gastric lavage and the administration of activated charcoal, are officially described as relevant measures for supportive management.

Connection to the Overall Overdose Profile: The official overdose profile requires the user to seek immediate professional attention for any ingestion of excess medication. This requirement exists because there is no known antidote, and management must proceed based on supportive care and the need for medical supervision and monitoring.

Therapeutic Uses of Zentel

What Zentel Treats: Main Uses and Benefits

Zentel (Albendazole) is applied across domains where additional symptomatic support is needed, and is used for managing parasitic infections caused by helminths and certain protozoa. It is commonly used for managing a range of conditions that affect both the gastrointestinal tract and the systemic circulation.

This includes addressing symptoms related to physical discomfort arising from common intestinal worms, such as roundworm, hookworm, whipworm, and pinworm, where the use of the medication helps ease the overall symptom burden. It is also relevant for easing symptoms related to heightened physiological activity linked to severe, long-term conditions like neurocysticercosis and hydatid disease. These are conditions where symptoms may intensify temporarily due to parasitic cysts in the brain or major organs.

The medication assists with maintaining functional stability and supports the patient during episodes of heightened discomfort. It is considered relevant in managing symptom clusters that may become intense or disruptive across various parasitic diseases, and is often applied in clinical settings that involve acute or unstable symptom patterns.

“The primary focus of therapy is managing symptoms that interfere with daily functioning and contribute to easing the overall symptom load.”


Quick Fact: Relief for Gastrointestinal Distress

Zentel is applied across domains where additional symptomatic support is needed in scenarios where acute discomfort and symptoms related to physical discomfort may be related to parasitic worms.

Regulatory References

  1. NIH MedlinePlus Drug Information

Eligibility and Restrictions for Use

Population Eligibility for Zentel (Albendazole)

The official regulatory labeling defines strict population-based eligibility criteria for the use of Zentel. Eligibility is determined by contraindications, age, reproductive status, and the presence of certain clinical conditions.

Eligibility Status Defined Populations (Regulatory Basis)
Contraindicated Individuals with known hypersensitivity to albendazole or other benzimidazole compounds. Women who are pregnant or are suspected of being pregnant.
Not Recommended Children under two years of age for most indications. Nursing mothers (breastfeeding should generally be discontinued).

Age-Based Restrictions

While use is established for adults and children two years of age and older, the medicine is not recommended for infants under two due to insufficient safety data. Limited clinical data is available for older adults (over 65 years), although specific dose adjustments are typically not required unless concurrent hepatic impairment is present.

Conditional Use Requirements

Patients with pre-existing hepatic disease or abnormal baseline Liver Function Tests are eligible only under conditional use, requiring close monitoring of liver enzymes before and every two weeks during treatment. Women of child-bearing potential must obtain a negative pregnancy test prior to initiation and use effective contraception during and for one month following therapy. This regulatory structure establishes clear boundaries for non-eligible and restricted-use populations.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Zentel's official regulatory documentation outlines specific pharmacokinetic and substance-related interactions that modify the concentration of the active metabolite, Albendazole sulfoxide.

Documented Exposure-Altering Interactions

Substance Regulatory Outcome (Concentration Change)
Dexamethasone Increases the steady-state trough concentrations of Albendazole sulfoxide by approximately 56%.
Praziquantel Increases the mean maximum plasma concentration ( C max) and area under the curve (AUC) of Albendazole sulfoxide by approximately 50% in the fed state.
Cimetidine Increases Albendazole sulfoxide concentrations in bile and cystic fluid by approximately 2-fold.

Metabolic and Inhibitory Effects

Regulatory agencies document that certain anti-epileptic agents, including Phenytoin, Carbamazepine, and Phenobarbital, may reduce plasma concentrations of Albendazole sulfoxide via enzyme induction. Conversely, Albendazole is documented to induce Cytochrome P450 1A ( CYP1A), leading to a regulatory recommendation to monitor plasma concentrations of CYP1A substrates, such as Theophylline, if co-administered.

Interaction-Related Constraints

  • Food Requirement: The systemic absorption of Albendazole is significantly enhanced by food; a high-fat meal is documented to substantially increase the systemic availability of the active metabolite.
  • Population-Specific Caution: Patients with documented hepatic impairment are identified in regulatory labeling as being at increased risk of adverse effects resulting from altered drug clearance and require closer monitoring.

Mechanism of Action

The mechanism of Zentel (Albendazole) is a highly selective process focused on the parasitic organism's cell structure and energy supply. It does not modulate human receptors but instead targets the biological processes within the helminths.

The Molecular Target: Inhibiting beta-Tubulin Assembly

The drug's active metabolite initiates its effect by binding selectively to the beta-tubulin subunit within the helminth's cells. This molecular interaction prevents the essential protein from assembling into microtubules, causing the degeneration and loss of the parasite's internal cellular structure. This mechanism is central to disrupting the processes dependent on the parasitic cytoskeleton.

Mechanistic Cascade: Blocking Nutrient Uptake and Energy

The structural damage to the microtubules has a critical physiological consequence: it cripples the parasite's ability to absorb vital nutrients, primarily glucose, from the host environment. This functional impairment leads to a sustained metabolic depletion cascade, depleting the parasite's stored glycogen and inhibiting the production of ATP (energy). This energy failure results in the parasite’s immobilization and subsequent death.

Constraints: Limits of Metabolic Action

The mechanism's success is directly constrained by the metabolic activity of the target organism. Therefore, the drug's action is weaker against inactive, old, or calcified cysts that are not actively engaging in nutrient uptake. The rapid death of certain parasites in closed tissues can trigger a secondary antigen release, inducing a host-driven inflammatory response as a consequence of the killing mechanism.

Dosage and Administration Information

How to Use Zentel: Administration and Dosing Principles

Zentel (albendazole) is an anthelmintic medication administered exclusively via the oral route. It is supplied as tablets and an oral suspension. A key administration requirement is that the medication must be consumed with food, specifically a fatty meal, as this significantly enhances the absorption and systemic availability of the active metabolite, a principle critical for effective use.

The practical dosing regimen is entirely dependent on the specific type of parasitic infection being managed. For the treatment of many common intestinal parasitic diseases, the pattern of use typically involves a single 400 mg dose.

Usage for Systemic Infections

For more complex, systemic infections, such as neurocysticercosis and hydatid disease, the medication is administered over an extended period using a twice-daily frequency:

  • Dose: Patients weighing 60 kg or more receive 400 mg twice daily (total of 800 mg/day). Patients weighing less than 60 kg receive a weight-based dose of 15 mg/kg/day divided into two doses.
  • Hydatid Disease Cycle: Treatment is structured in 28-day cycles of continuous use, which are separated by a 14-day drug-free interval, and typically repeated for a total of three cycles.
  • Neurocysticercosis Duration: The course is continuous, ranging from 8 to 30 days.

Administration Context

For patients with difficulty swallowing, the tablets may be crushed or chewed and swallowed with water. In terms of population-specific administration, the official labeling notes that dosage adjustment is generally not necessary for patients with renal impairment. However, in females of reproductive potential, treatment initiation requires a negative pregnancy test as a procedural prerequisite to administration.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Zentel

Evidence for Use in Neurocysticercosis (NCC)

Research exploring Zentel was studied for Neurocysticercosis (NCC), a condition where parasitic cysts develop in the brain, and has primarily involved Randomized Controlled Trials (RCTs). These studies were used in research exploring how symptoms change over time. The outcomes monitored in these trials were measurable patterns, such as the radiological change in active parasitic cysts and the monitored occurrence and frequency of seizures. The study populations included both adults and children who were observed with active NCC lesions. Findings describe patterns observed in the studies related to cyst measurements.

Evidence for Use in Cystic Hydatid Disease

The research base for Zentel was studied for Cystic Hydatid Disease—a condition where fluid-filled cysts form in organs like the liver or lung—involves a mixture of RCTs and long-term Observational Studies. The main outcomes research examined included measurements of cyst status and morphology, alongside the rate of cyst re-growth or recurrence over extended periods. Data show patterns related to cyst size and measurements of cyst status following treatment cycles. Findings were often based on a mixture of RCT and observational data.

Evidence for Common Intestinal Helminth Infections

Research for common Intestinal Helminth Infections (such as roundworm and hookworm) has mainly relied on large-scale Randomized Controlled Trials (RCTs). The research examined specific parasitological markers as primary outcomes, including the Parasitological Cure Rate (CR) and the Egg Reduction Rate (ERR). Data show patterns related to rates of parasitological cure and egg reduction for certain helminths. Study data were less consistent for outcomes examined with certain types of infection, such as whipworm.

What is Still Uncertain About Zentel Research

A key limitation is that evidence quality varies across studies depending on the specific parasitic infection being examined. Long-term effects are not fully established for all endpoints. While initial radiological and parasitological outcomes are monitored, research exploring long-term symptom management and functional stability is less developed. Furthermore, comparative evidence is lacking in some contexts, and data for certain groups (e.g., pregnant individuals) remain insufficient.

Key Studies & References

  1. Evidence-based guideline: Treatment of parenchymal neurocysticercosis - American Epilepsy Society
  2. Albendazole for the treatment of human echinococcosis: a review of comparative clinical trials - NCBI

Frequently Asked Questions (FAQ)

Common questions about Zentel (FAQ)


Q: How long does Zentel stay in your system after you finish treatment?

A: Official product information indicates that the drug’s active form, albendazole sulfoxide, typically has a half-life of about 8 to 12 hours. The half-life describes the time it takes for the amount of medication in the bloodstream to decrease by half. This time frame describes the period during which the drug is processed and cleared from the system.


Q: What happens if I take Zentel and I'm pregnant (before I know I am)?

A: Regulatory documents state that Zentel is contraindicated, meaning it should not be used, during pregnancy due to the potential for harm to the fetus. Regulatory information indicates that if a patient becomes pregnant while on the medication, the drug should be discontinued promptly. This is why official guidelines note the requirement of a negative pregnancy test before treatment initiation for females of reproductive potential.


Q: Are the side effects from Zentel usually mild or severe?

A: Official safety documents list side effects across several categories, including common effects such as headache, nausea, and abdominal pain. However, these documents also include warnings about rare but serious adverse reactions, such as severe bone marrow suppression or acute liver failure. Regulatory agencies mandate routine monitoring of blood cell counts and liver enzymes during treatment to safely manage these risks.


Q: Do the side effects of Zentel stop immediately after I stop taking it?

A: Official product information suggests that many of the changes caused by the medicine, such as the elevation of liver enzymes and reversible hair thinning (alopecia), are described as transient. This means they are temporary and are generally expected to resolve once the treatment course is finished.


Q: Is Zentel effective against all types of worm infections?

A: Zentel is generally recognized as a broad-spectrum medication, meaning it is indicated for the treatment of a wide variety of parasitic worm infections. However, official studies indicate that the results related to efficacy, such as the rate of parasite clearance, may be less consistent for certain infections, including whipworm.


Q: Is Zentel a type of antibiotic, or is it different?

A: According to official classification, Zentel is not an antibiotic. The medicine is instead classified as an anthelmintic agent, which means its purpose is to specifically treat infections caused by parasitic worms.


Q: Are there any common foods or drinks that should be avoided when using Zentel?

A: Official patient information sometimes advises against consuming grapefruit or grapefruit juice while taking albendazole, as these can affect drug levels. Heavy consumption of alcohol is often mentioned as an area of caution, as it may theoretically increase the risk of certain side effects.


Q: Can Zentel cause changes to my urine or stool?

A: Safety warnings for the medication note that serious liver problems are a risk, and these can sometimes be indicated by changes such as dark urine or light-colored stools. In addition, blood in the urine or stools is a rare side effect that has been noted in postmarketing reports.


Q: If I miss a dose of Zentel, what generally happens?

A: Patient information leaflets describe the typical approach for a missed dose, which often involves taking the dose when remembered. However, if it is almost time for the next dose, the guidance suggests skipping the missed dose to avoid taking a double dose.


Q: Does Zentel affect your immune system?

A: Regulatory documents indicate a risk of bone marrow suppression, which can result in lower white blood cell counts (leukopenia). Since white blood cells are critical for fighting infection, this effect is relevant to the body's immune function. Official guidelines mandate routine blood cell counts during treatment to monitor this effect.


Q: Does Zentel make you feel sleepy or affect your ability to drive?

A: Official product information notes that side effects such as dizziness, vertigo, or somnolence (sleepiness) may occur. Official product information notes that patients should be aware of how the medicine affects them before engaging in activities like driving or operating machinery.


Q: Why is alcohol generally discouraged while taking Zentel?

A: Official guidance generally advises caution when using alcohol concurrently with this medicine, as with many others. While a specific clinical interaction is not always listed, alcohol consumption may theoretically increase the severity of certain side effects.


Q: Can Zentel interact with herbal supplements like St. John's Wort?

A: Regulatory documents list several drug interactions involving liver enzymes, which is often the concern with herbal supplements like St. John's Wort. Regulatory documents note that patients typically inform a healthcare provider about all products they are taking, including herbal supplements and vitamins, to check for potential unlisted interactions.


Q: What are the main warning signs of a serious allergic reaction to Zentel?

A: Safety information notes that signs of a serious allergic reaction often include the appearance of hives, swelling in the face, lips, tongue, or throat, and difficulty breathing. Serious skin reactions have also been reported in postmarketing data.


Q: If I feel better, should I still finish the full course of Zentel?

A: Patient information describes the importance of completing the full course of medication as prescribed, even if a patient starts feeling better quickly. Finishing the complete regimen is important for the regimen's intended effect and to address concerns about drug resistance.


Q: Does Zentel have any known 'black box' warnings in the US?

A: The FDA Prescribing Information for Zentel does not currently include a Boxed Warning, sometimes referred to as a 'Black Box' warning. However, the document does contain serious warnings and precautions related to risks like bone marrow suppression and potential harm to a fetus.


Q: Why is it important to confirm the type of infection before starting Zentel?

A: Regulatory documents show that the specific parasitic infection being treated determines the required dosing and duration of the medication. For instance, the regimen can range from a single dose for some infections to multiple cycles over an extended period for others.


Q: Are there any specific lifestyle changes recommended when taking Zentel?

A: Official advice often focuses on preventing complications associated with the documented risks of the medication. For example, if treatment causes low white blood cell counts, patients may be advised to take precautions like avoiding crowds to reduce the risk of infection.


Q: Are there any long-term health concerns associated with using Zentel?

A: Official labeling mandates regular monitoring of blood cell counts and liver enzymes for patients on extended courses due to documented risks of bone marrow suppression and liver injury. Furthermore, regulatory research reviews note that the effects of long-term use for some therapeutic endpoints are not fully established.


Q: How often do people report serious side effects from Zentel?

A: Regulatory authorities classify side effects based on how often they are reported in clinical studies or post-marketing surveillance. Serious adverse events, such as bone marrow suppression or acute liver failure, are documented as being rare or infrequent occurrences.

How should Zentel be stored and disposed of?

How to Store and Dispose of Zentel (Albendazole)

Official regulatory documentation requires that Zentel tablets and suspension be stored under specific conditions to maintain stability.

Storage Requirements

The medicine must be stored at a temperature below 30 C and protected from freezing. It should be kept in a cool, dry place away from moisture and direct sunlight. The product must remain in its original, tightly closed container until use. A mandatory requirement is to keep Zentel out of the reach and sight of children.

Disposal Instructions

Zentel must not be used after the expiry date printed on the packaging. Unused or expired medication should not be disposed of via wastewater or household waste to prevent environmental contamination. The product must be discarded in accordance with local regulations, often by returning it to a pharmacy for safe pharmaceutical waste disposal.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Zentel found in:

A-Z Index: